Success Metrics

Clinical Success Rate
100.0%

Based on 11 completed trials

Completion Rate
100%(11/11)
Active Trials
0(0%)
Results Posted
73%(8 trials)

Phase Distribution

Ph phase_1
1
8%
Ph phase_3
4
33%
Ph phase_4
7
58%

Phase Distribution

1

Early Stage

0

Mid Stage

11

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
1(8.3%)
Phase 3Large-scale testing
4(33.3%)
Phase 4Post-market surveillance
7(58.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

91.7%

11 of 12 finished

Non-Completion Rate

8.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(11)
Terminated(1)

Detailed Status

Completed11
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (8.3%)
Phase 34 (33.3%)
Phase 47 (58.3%)

Trials by Status

withdrawn18%
completed1192%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_4

Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax

NCT04555694
completedphase_4

A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%

NCT01437982
completedphase_4

Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis

NCT01443442
completedphase_3

Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.

NCT01475643
completedphase_1

Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations

NCT03098953
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT04555694Phase 4

Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax

Completed
NCT01437982Phase 4

A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%

Completed
NCT01443442Phase 4

Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis

Completed
NCT01475643Phase 3

Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.

Completed
NCT03098953Phase 1

Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations

Completed
NCT01853696Phase 4

Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty

Completed
NCT00699153Phase 3

Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery

Completed
NCT00705159Phase 4

Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis

Completed
NCT02028312Phase 4

A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®

Withdrawn
NCT01724892Phase 4

Comparison the Effects of Dexamethasone and Loteprednol on Epithelial Healing

Completed
NCT01060072Phase 3

Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery

Completed
NCT01010633Phase 3

Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12